Caladrius Biosciences to Participate in Upcoming Conferences
April 03 2019 - 8:30AM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company committed to the development of innovative products that
have the potential to restore the health of people with chronic
illnesses and with a focus on select cardiovascular indications,
announced today that David Mazzo, Ph.D., President and Chief
Executive Officer of Caladrius Biosciences, will present a
corporate overview at the following upcoming conferences:
26th Annual Future Leaders in the Biotech
Industry
|
Date & Time: |
Friday, April 12, 2019 at 9:30 a.m. (EDT) |
|
Venue: |
Millennium Broadway Hotel & Conference Center
in New York City |
Planet MicroCap Showcase 2019
|
Date & Time: |
Wednesday, May 1, 2019 at 10:30 a.m. (PDT) |
|
Venue: |
Bally's Hotel & Casino in Las Vegas |
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
committed to the development of innovative products that have the
potential to restore the health of people with chronic illnesses.
Our leadership team collectively has decades of biopharmaceutical
development experience and world-recognized scientific achievement
in the fields of cardiovascular and autoimmune disease, among other
areas. The Company’s goal is to build a broad portfolio of novel
and versatile products that address important unmet medical needs.
Our current product candidates include three developmental
treatments for cardiovascular diseases based on our CD34 cell
therapy platform: CLBS12, recipient of SAKIGAKE designation, in
Phase 2 testing in Japan and eligible for early conditional
approval for the treatment of critical limb ischemia; CLBS14-CMD,
in Phase 2 testing for the treatment of coronary microvascular
dysfunction; and CLBS14-NORDA (formerly CLBS14-RfA) in late-stage
development for no option refractory disabling angina for which it
has received RMAT designation. For more information on the company,
please visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Sep 2023 to Sep 2024